Back HCV Treatment

Combination Therapy with Investigational HCV Polymerase Inhibitor R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV

Due to the limited efficacy and side effects of standard hepatitis C therapy using pegylated interferon (Pegasys or PegIntron) plus ribavirin, researchers are studying several oral agents that directly target various steps of the hepatitis C virus (HCV) lifecycle. One such agent, Pharmasset's R7128 (a prodrug of the nucleoside analog HCV polymerase inhibitor PSI-6130) is currently in Phase 1 clinical trials, in combination with Pegasys plus ribavirin. In August, the company reported preliminary data from a cohort of patients with hard-to-treat HCV genotype 1. This week, Pharmasset reported early results from a subgroup of participants with easier-to-treat genotypes 2 or 3.

Read more: